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Abstract
Introduction: Harmonized neuropsychological assessment for neurocognitive disor-
ders, an international priority for valid and reliable diagnostic procedures, has been
achieved only in specific countries or research contexts.
Methods: To harmonize the assessment of mild cognitive impairment in Europe, a
workshop (Geneva,May 2018) convened stakeholders, methodologists, academic, and
non-academic clinicians and experts fromEuropean, US, and Australian harmonization
initiatives.
Results:With formal presentations and thematic working-groups we defined a stan-
dard battery consistent with the U.S. Uniform DataSet, version 3, and homogeneous
methodology to obtain consistent normative data across tests and languages. Adapta-
tions consist of including two tests specific to typical Alzheimer’s disease and behav-
ioral variant frontotemporal dementia. The methodology for harmonized normative
data includes consensus definition of cognitively normal controls, classification of con-
founding factors (age, sex, and education), and calculation of minimum sample sizes.
Discussion: This expert consensus allows harmonizing the diagnosis of neurocognitive
disorders across European countries and possibly beyond.
KEYWORDS
Alzheimer’s disease, cognitive assessment, diagnosis, mild cognitive impairment, mild neurocog-
nitive disorders, standard neuropsychological assessment
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1 INTRODUCTION
A key early step in the clinical diagnostic process for persons with cog-
nitive complaints who are referred tomemory clinics consists of ascer-
taining the presence of objective cognitive impairment1,2 by examin-
ing performance on a set of neuropsychological tests. As shown in
Supplemental Table S1, different tests are more sensitive to differ-
ent disorders. Heterogeneous batteries could therefore result in dif-
ferent diagnoses for patients. Reliable clinical actions require that
different diagnostic procedures operationalize the definition of the
target clinical disorder consistently. One way to accomplish this is
by consistent test selection. Such standard procedures would enable
the use of biomarkers and treatment in line with their demonstrated
informative or therapeutic value, and uniformly across centers. In
the same way, valid research procedures require consistent opera-
tionalization of the same clinical construct across research settings.
It is therefore desirable that the selection of patients who are eli-
gible for the full diagnostic procedure or for research studies be
based on a standard common neuropsychological assessment, oper-
ationalizing the target condition consistently.3,4 Post hoc computa-
tions permit alignment of scores from heterogeneous batteries and
pooling of data from different centers for research aims,5,6 thereby
facilitating analyses of large multi-site data sets. Such computations,
however, cannot amend the upstream inclusion of heterogeneous
patients.
Many efforts have been made to tackle this problem, providing
resources to support harmonization (Supplemental Table S2). For
example, many US research centers have been able to standardize
neuropsychological assessments on a large scale.7 Similarly, German-
speaking countries widely adopted the Consortium to Establish a Reg-
istry for Alzheimer’sDisease–Neuropsychological Assessment Battery
(CERAD-NAB) for thediagnosis of patientswithdementia (Supplemen-
tal Table S2), and recently, a Chinese effort defined a standard bat-
tery for clinical use.8 This work aims toward standardizing neuropsy-
chological assessments for detecting mild cognitive impairment (MCI)
consistently in people attending European memory clinics with cogni-
tive complaints.We leveragedprevious initiatives and incorporated the
complementary expertise of academic and non-academic clinicians to
provide standard procedures that will reduce costs and effort in clinics
and benefit research activities.
2 METHODS
This initiative follows the Strategic Biomarker Roadmap, a method-
ological framework specific to biomarker validation, adapted from
oncology to the field of dementia. This framework outlined the appro-
priate sequence of validation steps for diagnostic biomarkers, and the
priority of standardizing neuropsychological assessment as a prereq-
uisite for their proper validation.4,9 Because many studies of clinical
validity and utility are performed on patients frommemory clinics, har-
monizingneuropsychological assessment for the clinical settingswould
RESEARCH INCONTEXT
1. Systematic review: With inclusive strings, we identi-
fied literature, resources, projects, and participants for a
workshop to harmonize neuropsychological assessment
for European clinics, as existing initiatives were either
limited to individual countries or to research settings
(Table S2).
2. Interpretation: Our consensus Clinician’s Uniform
Dataset (cUDS), similar to UDS-3, and our methodology
for generating harmonized norms would (a) improve
detection of Alzheimer‘s disease (AD) and of non-AD
or atypical-AD syndromes in mild cognitive impairment
(MCI); (b) reduce costs; (c) benefit patients, health care
systems, and clinical research within a consistent frame-
work; (d) align clinical and research procedures; and (e)
achieve modern, reliable, and cost-effective standard of
care for neurocognitive disorders.
3. Future directions will consist of exploring hurdles and
needs to implement the cUDS in academic and non-
academic memory clinics, creating and validating local
versions for European languages, and creating tools to
support adoption.
have double benefit, improving research as well as clinical procedures
at once.
A workshop (Geneva, May 9-11, 2018) was hosted by the European
Alzheimer’s Disease Consortium (EADC), the Geneva Memory Clinic,
the Centre Interfacultaire de Gérontologie et d’Études de Vulnerabil-
ité (CIGEV), and Swiss Memory Clinics. Participants were European
dementia experts—physicians, neurologists, (neuro)psychologists, psy-
chiatrists, geriatricians—from non-academic and academic memory
clinics, researchers from previous pertinent harmonization initiatives
worldwide, methodologists, and stakeholders (https://cigev.unige.ch/
files/5015/3788/2053/hnade.pdf) (see Supplemental Box S1 for insti-
tutions and their representatives and Supplemental Box S2 for indi-
vidual participants and affiliations). At the workshop, presenters
described the methods, results, issues, and resources from previous
harmonization initiatives, and current development of tests specific
to dementing neurodegenerative disorders in plenary sessions. After
the plenaries, participants were assigned to specific thematic sub-
groups based on their expertise and leveraging published evidence, to
work in parallel and find solutions to harmonize the aspects specific to
their competence (neuropsychology experts: test selection; statistics
experts: modeling for the generation of normative values; digital work-
ing group: potential and issues on digital-assisted testing).
All of the consensual decisions reported in Results derive from the
following procedure (Figure 1).
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F IGURE 1 Consensus procedure used for defining the cUDS and themethods to generate harmonized normative values
2.1 Thematic subgroups
Each thematic subgroup was led by one expert (two in the case of
the statistical working group) to help discussions through a semi-
structured approach. They elaborated on methodology (methods
to define normative values; statistical approaches/modeling), issues
related to neuropsychological tests (test selection; hypothesis-driven
test generation), and digitally assisted testing. At the workshop, the
subgroups developed proposals for defining the normal population,
confounding factors and minimum sample size required to produce
consistent normative values, test selection for standard assessment,
and perspectives for future consideration. Decisions were proposed,
discussed, refined, and ratified in subsequent plenary discussions
with informal consensus procedures. For some aspects, the subgroups
were tasked to further process their topics after the workshop. Sub-
groups completed the processing of their tasks in the followingmonths
through online meetings and provided written sections for the paper
and the supplemental material. All participants were entitled to object
and contribute. Divergence was settled based on published data, pro-
cessed by the pertinent thematic working group after the workshop.
When no further objections emerged for solutions to previous objec-
tions, we considered that themajority agreed on the latest solution.
2.2 Consensus refining
After the workshop, the moderator (first author) incorporated the
achieved consensus decisions into a first draft paper. Additional con-
tributors were invited to provide information and knowledge based on
their expertise in the field, and their comments were accommodated
into themanuscript.Workshop participants and the additional contrib-
utors could access the manuscript at all phases, and proposed com-
ments were accessible to all. Whenever objections and disagreement
requiring specific expertise arose, the moderator consulted the the-
matic subgroups again for qualified processing. This was done through
both in-person or remote meetings. Both expertise and published evi-
dence were used to support decisions.
2.3 Quantification of final consensus
At the end of this procedure, participants could express their (a) full
agreement, (b) partial agreement (ie, agreeas a first step, in viewofnext
improvement), or (c) disagreement, and could propose reasons and fur-
ther comments through a formal voting system. Those who took part
in the workshop in person and the additional contributors based in
Europe were invited to this final vote (N = 47). Because all of the pro-
posed points came from a lengthy (although informal) consensus pro-
cedure, we set the threshold for agreement at 90%. Both the options
“Full” and “Partial agreement in view of future improvement” were
considered as agreement for the current decision, “Partial agreement
in view of future improvement” meaning that the current solution is
a required interim step toward harmonization. Answers of partial or
lacking agreement required explanation of reasons. These were used
to further improve the final manuscript, or processed as far as possible,
fed back to all participants blinding the identity of individual respon-
ders, and stored to support next developments.
2.4 Definition of sample size
The statistical subgroup started with a general-purpose estimation
method to pinpoint the number of subjects required to compute nor-
mative values with correction parameters based on the consensual
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classification of confounding factors.10 A simulation procedure was
then used to compute the minimum sample size per language that
would allow for (a) stable computations across different scenarios (eg,
different distribution properties of test scores, adjustments for con-
founding factors) and (b) use of complex computational procedures
(eg, ItemResponse Theory, Structural EquationModels) to allowdevel-
opment of flexible composite measures.5 Additional computational
details are provided in Supplemental Section 1.
3 RESULTS
Consensuswas achieved and formalized (1) on a proposal for aUniform
Dataset analogous to that produced by the U.S. National Alzheimer’s
Coordinating Center (NACC) (Table 1)7 for the context of use of diag-
nosis in memory clinics, and on enriching it with tests specific to the
pathophysiology of typical Alzheimer’s disease (AD) and behavioral
variant frontotemporal dementia (bvFTD); (2) on a standard definition
of normal controls (Box 1), aimed to produce consistent normative val-
ues; and (3) on a standard methodology to produce harmonized nor-
mative data across tests and languages (Box 1; Table 1). The main next
steps will require refining the harmonization as emerged from the dis-
cussions and to proceed toward implementation (Box 2). Forty-two of
the 47 invited participants and contributors sent their final votes and
comments at the final questionnaire. Formal consensus with the deci-
sions expressed in the final manuscript was 100% for all points. Par-
tial agreement that could not be fully accommodated in thismanuscript
amounted to three voters (7%) for the adoption ofUDS-3 and the inclu-
sion of FCSRT and the Story-Based Empathy Task (SET), two (5%) for
the definition of normal controls, one (2%) for the inclusion and exclu-
sion criteria of controls, none for themethodology to provide standard
normative values, and two (5%) for the next harmonization steps.
3.1 Context of use
Workshop participants agreed on the need and timeliness of a harmo-
nization initiative for neuropsychological assessment for memory clin-
ics and its concomitant utility for clinical research, and on the need to
encourage a collaborative and representative participation of differ-
ent clinical contexts and countries. Although aimedat European clinical
settings, the intrinsic European cultural and linguistic heterogeneity,
the high rate of migration, and the need to leverage existing resources
and to align the clinical and clinical-research contexts motivated par-
ticipants to consider this effort within a broader European and non-
European context. This effort has been aimed primarily at clinical use,
but its applicability to clinical research is straightforward.
The proposed primary objective of the anticipated standard assess-
ment is to reliably identify MCI and progression of cognitive decline
in persons referred to memory clinics, or other specialized centers, for
cognitive complaints. The assessment is not designed to detect subtle
deficits in the preclinical disease phase, or to grade severity of impair-
ment at the dementia stage.Moreover, it is not designed for population
screening, case finding, or finer cognitive profiling aiming at other pur-
poses (eg, to formulate etiopathological diagnoses based on cognitive
profile, or to tailor neuropsychological rehabilitation).
3.2 Uniform data set
Workshop participants proposed and consented to adopt version 3 of
the U.S. NACC Uniform Dataset (UDS-3) neuropsychological test bat-
tery, to date the most widely implemented standard battery for diag-
nosing MCI and measuring progression of cognitive decline in early
dementia. The main reasons for partial agreement in view of future
improvement in the formal voting for final agreement included the
length of the proposed battery, possibly excessive for some clinics, as
well as requests for even more extensive and thorough assessment; a
limited added value over current harmonization in countries already
using standard batteries (ie, The Netherlands and German-speaking
countries); and possible issues on administration, scoring, and norms.
The following integrations were required to increase sensitivity to
MCI.
3.2.1 Adaptations
The UDS-3 largely consists of new, copyright-free versions of common
neuropsychological tests that are sensitive to MCI and early dementia
cognitive decline andovercome test repetition effects7,11 (Table1). The
tests were specifically developed, adapted, and normed for the elderly
U.S. population. The first step for the European harmonization is to
adopt European “local analogues”, that is, traditional tests with local
normative values analogous to those in the UDS-3, like the WAIS digit
span instead of the UDS-3 number span, or the Boston Naming Test if
local norms for MINT (Multilingual Naming Test) are lacking (Table 1).
Subsequent steps require adapting tests across languages and acquir-
ing local normative data (Box 2). Another possible adaptation relates
to test order. If tests are already used in local batteries, with different
order due to different composition of such batteries, such order dis-
crepancies are considered compatiblewith this harmonization effort at
this stage.
3.2.2 Integration
Workshop participants also agreed on including tests specific to
episodic memory and emotional cognition impairment (bold in Table 1)
to provide better coverage of these cognitive domains in line with
Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition
(DSM-5) guidelines, and to enhance the battery’s sensitivity to the typ-
ical AD, atypical AD, and to bvFTD. Specifically, they proposed replac-
ing the Craft Story Memory test (the UDS-3 replacement of the logi-
cal memory test) with the verbal version of the Free and Cued Selec-
tive Reminding Task (FCSRT),12 and adding the Story-based Empa-
thy Task (SET)13 to assess social competence. The Free and Cued
Selective Reminding Task (FCSRT)12,14 is a cued word list task pro-
viding controlled learning and retrieval conditions that enable one to
6 BOCCARDI ET AL.
TABLE 1 UniformDataset, based on the current US standard for research (UDS-3(1)) and the GenevaWorkshop 2018 adaptation to clinical
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General cognitive
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or Boston naming test,
if lacking norms
comprehension
Total time 52-57′ 60-65′
Tests in italics denote “local analogues,” that is, traditional local versions of the UDS-3 tests. Bold (besides titles) denotes tests added or replaced to
UDS-3 tests. “Order” denotes the presentation order in UDS-3 as from https://www.alz.washington.edu/NONMEMBER/UDS/DOCS/VER3/UDS3_npsych_
worksheets_C2.pdf and the administration order of the cUDS tests as described in the Results section. Time denotes expected duration of administration
estimated for patients with MCI (with CDR test score between 0.5-1) and including instructions. MINT=Multi-lingual naming test; FCSRT = Free and cued
selective reminding test, verbal version(4); MoCAMontreal Cognitive Assessment.
*Category fluency andMINT also have a long-termmemory component.
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distinguish between impaired encoding (eg, due to attention disorders
as in depression), storage (eg, due to hippocampal damage as in typ-
ical AD), and recall strategies (eg, due to frontal lobe dysfunction).3
Impaired task performance in the FCSRT correlates with in vivo
AD biomarkers,15 even at the prodromal stage.16,17 Low total recall
performance despite retrieval facilitation with cueing discriminates
MCI patients subsequently converting to AD dementia with 88.6%
specificity,18 showing better diagnostic and prognostic performance
than the LogicalMemory task.16,17,19–22 The FCSRThas been validated
in many EU countries, with normative values available in different lan-
guages (see Table 1). The verbal version of the FCSRT has lower ceil-
ing effects and greater dispersion of test scores,23,24 and is therefore
preferred over the visual version for a standard assessment. The SET
was specifically developed to assess social cognition in patients with
dementia. It requires subjects to select the possible endings of sto-
ries told with cartoons, and assesses emotion and intention attribution
separately, as well as causal inference as the control condition. Ver-
bal interaction is used to ascertain proper comprehension of instruc-
tions; however, correct performance consists of selecting the correct
story ending among the available pictures. Similar to the mini Socio-
Emotional Assessment (mini-SEA),25, performance on the SET13 cor-
relates with structural and functional imaging evidence of frontal lobe
8 BOCCARDI ET AL.
BOX 1 Consensual definition of Normative Population to obtain consistent normative values across countries and tests. All of the reported
criteria must bemet to recruit proper harmonized control samples
Selection of normal (not super-normal) subjects
∙ Bias-free recruitmentmodalities (eg, to guarantee representativeness for the whole country population, recruitment should avoid clustered data
within just one site, and data should be gathered pairwise—for age, sex, education—within each recruitment site)
∙ Avoid convenience samples unless compliant with the inclusion/exclusion criteria
∙ Avoid voluntary exclusion of otherwise healthy individuals positive to biomarkers for brain amyloidosis, tau, or other neurodegeneration that
define risk or preclinical stage for neurocognitive disorders
∙ Avoid voluntary exclusion of subjects with subjective cognitive decline (SCD) from samples explicitly recruited as normal controls
∙ Do not seek demonstration of stable cognitive health with longitudinal neuropsychological and neurological assessment (“robust norms”)
Inclusion Criteria
∙ Age: if feasible, 40 years or older
∙ Self-identified as “cognitively normal”
∙ Denies a worrying cognitive decline
∙ Judged to be cognitively normal by a family member (or other knowledgeable informant); cut-off of 3.3 on the short form of the Informant
Questionnaire on Cognitive Decline (IQCoDe)(1) or equivalent




∙ Sensory or motor deficits interfering with test administration
∙ Continuousmoderate-to-intense pain
∙ Current psychiatric diagnosis (includingmajor depression). Geriatric Depression Scale (15-items) score of 6 or greater (4)
Medical history
∙ Head injury with loss of consciousness for more than 5minutes
∙ General anesthesia within the last 3months
∙ Prior recurrent psychiatric disorder requiring hospitalization
∙ Use of psychoactive drugs, alcohol abuse
∙ Significant cerebrovascular disease (eg, TIA, stroke, general atherosclerosis)
∙ Severe activemedical condition (cancer, organ failure, unstable heart condition) that may interfere with test administration
Convenience samples
∙ May be used if compliant with the above features
∙ May be used ad interimwhen proper samples are unavailable
∙ Specific research samples (only SCD, or composed of subjects all having specific risk factors) are not appropriate
References.
1. Quinn TJ, Fearon P, Noel-Storr AH, Young C,McShane R, Stott DJ. InformantQuestionnaire on Cognitive Decline in the Elderly (IQCODE) for the diagnosis
of dementia within community dwelling populations. CochraneDatabase Syst Rev. 10 aprile 2014;(4):Cd010079.
2. Roalf DR, Moberg PJ, Xie SX, Wolk DA, Moelter ST, Arnold SE. Comparative accuracies of two common screening instruments for classification of
Alzheimer’s disease, mild cognitive impairment, and healthy aging. Alzheimers Dement. settembre 2013;9(5):529-37.
3. van Steenoven I, Aarsland D, Hurtig H, Chen-Plotkin A, Duda JE, Rick J, et al. Conversion between mini-mental state examination, montreal cognitive
assessment, and dementia rating scale-2 scores in Parkinson’s disease. MovDisord. dicembre 2014;29(14):1809-15.
4. Friedman B, Heisel MJ, Delavan RL. Psychometric properties of the 15-item geriatric depression scale in functionally impaired, cognitively intact,
community-dwelling elderly primary care patients. J AmGeriatr Soc. settembre 2005;53(9):1570-6.
impairment26. Although further studies on comparativediagnostic per-
formance across social cognition tests and European cultural contexts
are warranted, we propose the SET because it was developed specifi-
cally for bvFTD patients, and it places a minimum load on non-target
cognitive functions such as language andworkingmemory.
3.2.3 Administration procedure
The total administration time for the cUDS is estimated to be 60-65
minutes for patients with MCI. The delay interval required between
immediate and delayed trials of the FCSRT12,14 is filled with adminis-
tration of the non-verbal Trail Making A and B and SET13, allowing the
delay to be free from interference from other verbal tasks27 (Table 1).
3.3 Harmonized methodology to produce
normative values
Workshop participants highlighted the priority of defining normative
values basedon standardmethodology to guarantee consistent assess-
ment of performance across tests and languages. Therefore, they
BOCCARDI ET AL. 9
BOX 2 Roadmap of required actions towards a harmonized cognitive assessment
Immediate actions for
implementation Next actions for implementation
Medium term development of harmonized
assessment
If possible, use cUDS as from
Table 1
If not possible, adopt local
analogues (differences in
administration order are
admitted, when the cUDS tests
are already used in local
batteries guaranteeing
appropriate administration
relative to delay, interference,
etc.)
Define a standard format for data
entry and for the clinical report
Coordinate next steps
consistently across countries
to get aligned asmuch as
possible (e.g., exact version of
tests)
Extend representativeness of the
consortium
Perform survey to explore feasibility,
hurdles, facilitators and needs for
implementing cUDS in academic and
non-academicmemory clinics
Potentiate reciprocal connection of
research and clinical centers
Offer services to clinicians, to:
∙ connect and receive feedback
∙ support compliance to
harmonization
∙ Define copyright-free cUDS tests in
the sameway as done for UDS-3 (1)
∙ Provide local normswith the
harmonizedmethodology proposed
here (labs of neuropsychology)
∙ Bridge with pertinent stakeholders
(e.g., health refunders, regulators) for
consistent implementation
∙ Identify tests most needed to
complete appropriately cUDS
(uncovered domains; actual
administration time & tasks for
interference/delay; etc.)
Adapt tests across European cultures and languages
Develop alternate test versions for repeated testing
Validate cUDS:
∙ for most widespread languages first
∙ for the 27 EU languages (include language variant
sub-samples in main languages)
∙ based on the defined harmonizedmethods
∙ both paper-pencil and tablet version if available
∙ Define backwards compatibility to shift from
currently used batteries to the standard
∙ Disseminate the information about cUDS
implementation capillary through clinical and
professional networks and Scientific Societies
∙ Adapt tests for digitally-assisted assessment (tablet)
∙ Converge informatics experts and entrepreneurs to
overcome issues on digitally-assisted assessment
∙ Possibly includemore, or more sensitive, tests,
thanks to digital advancements
∙ Keep developing hypothesis-driven and culture-free
tests, and validate them based on the consensually
definedmethodology
∙ Consider the use of robust controls to compare, and
possibly improve, normative values and test
sensitivity in the future
∙ Select newly developed tests based on diagnostic
performance
∙ Fine-tune cUDS and implementation based on
consensus with all stakeholders
1. Weintraub S, Besser L, Dodge HH, Teylan M, Ferris S, Goldstein FC, et al. Version 3 of the Alzheimer Disease Centers’ Neuropsychological Test Battery in
the UniformData Set (UDS). Alzheimer Assoc Disord. marzo 2018;32(1):10-7. .
developed a standard definition of the normal population, defined how
to code confounders of normative data consistently, and proposed the
minimum necessary requirements for the normative sample size.
3.3.1 Normal population
Thenormal population thatwill provideharmonizednormativedata for
the proposed context of use must consist of individuals without cogni-
tive decline, functional impairment due to cognitive deterioration, or
major clinical conditions that could interfere with cognition (Box 1).
Main reasons for partial agreement in view of future improvement in the
formal voting for final agreement relate to the potential appropriate-
ness of robust controls. At present, recruitment of normal controls
from the general population should not exclude cognitively unimpaired
individuals who may have positive biomarkers or specific risk factors
(eg, APOE ε4 allele) forAD, nor should it target the “super-normal” indi-
viduals (also described as “robust controls”) with longitudinal evidence
of preserved cognition, although this will plausibly be a required future
development (Box 2). Convenience samples of cognitively normal indi-
viduals may be employed only if they were recruited to serve as nor-
mal controls and if compliant with the criteria reported in Box 1. Con-
venience cognitively normal samples should not consist of individuals
recruited as target experimental cases (eg, people with subjective cog-
nitive decline or otherwise at risk for neurocognitive disorders). One
reason for partial agreement in view of future improvement in the formal
voting for final agreement on the individual exclusion/inclusion crite-
ria in Box 1 consisted in disagreement on excluding people who expe-
rienced post-traumatic loss of consciousness without significant mem-
ory loss.
3.3.2 Demographic factors affecting
neuropsychological performance
Standard classification was proposed for age, sex, and education, the
main variables that often affect neuropsychological test performance
and should be accounted for in normative data. Panelists agreed that
normative data and test cut-off values should be stratified across
6 age decades, from the 40 to the upper 90+ year age categories,
with balanced sex and education level in each age category. To code
education consistently across countries, we adopted the three-level
coding system from the International Standard Classification of
Education (ISCED) of the United Nations Educational, Scientific and
Cultural Organization (UNESCO) https://ec.europa.eu/education/
international-standard-classification-of-education-isced_en). This
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system includes (1) compulsory (primary and secondary) education
(age range: min = 5, max = 17), (2) upper-secondary education (age
range for EU countries: min = 12, max = 19), and (3) post-secondary
education (age range: min= 18, max≥22) (Supplemental Table S3).
3.3.3 Sample size
The above classification scheme defines 36 cells that encompass six
age classes by three educational levels by two sexes (Supplemental
Table S4). Our sample size computation estimated that 10 subjects per
cell would suffice to perform general linear models (see Supplemen-
tal Section-1 for computational details). Data from this carefully con-
structed sample can be used to normalize standard scores or modern
psychometric scores derived from ItemResponse Theory or Structural
Equation Modeling. An estimated sample size of N = 330 subjects per
language28–30 provides a fair trade-off between feasibility and reliabil-
ity, whereas taking into account the stratifications for age, education,
and sex (although cells covering rare populations, eg, age 90+with high
education, may be hard to fill) (Supplemental Table S4).
3.3.4 Test validation
The cUDS neuropsychological tests should ideally be copyright-free
versions, analogous to the U.S. UDS-37, which are adapted to the var-
ious European target languages. They should be validated in all Euro-
pean languages, taking care to include linguisticminorities in validation
studies.
Achieving a standard assessment of this kind requires additional
research steps (see roadmap outlined in Box 2). A reason for partial
agreement in view of future improvement in the formal voting for final
agreement on such roadmap consisted in the difficulty of harmonizing
and producing culture-free social cognition among countries. Another
main hurdle lies in the fact that some countries already use CERAD or
other batteries as local standards. However, using the cUDS, as a com-
mon set of UDS-3 or analogous tests with locally appropriate norma-
tive data was seen as a first practical step towards harmonization.
4 DISCUSSION
This work defines the first steps toward a standard assessment of peo-
ple with cognitive complaints attending European memory clinics or
participating in clinical research on MCI in Europe. This assessment
includes a standard neuropsychological test batterywith a harmonized
methodology to produce normative data and cut-off values for impair-
ment. Besides leveraging on previous harmonization efforts, the bi-
directional collaborationwith clinicians fromspecialized non-academic
centers is a new and important step necessary to fit the needs and
constraints of both clinical practice and research. With evolving clini-
cal criteria and the availability of biomarkers with specific diagnostic
value, it is now even more important to assess patients consistently
with a precise definition of the target disorder, with the demonstrated
informative value of diagnostic biomarkers, and across centers. With
standard assessment, patients could get second opinions or receive
follow-up examinations in different centers without the need to repeat
existing baseline assessments. Costs, as well as practice effects, would
be reduced; benefits for data pooling and comparability of studies in
clinical research are straightforward. The reliability of diagnostic pro-
cedures for MCI may improve and approach the quality standards of
other clinical conditions.
The proposed standard assessment is not designed to ascertain the
pathophysiology underlying cognitive impairment, but to detect the
presence and possibly progression of objective cognitive decline that
may be due to a neurodegenerative condition. Further exploration,
increasingly performed through biomarkers, is required to formulate
an etiopathological diagnosis or to identify specific clinical needs.
The cUDS is based on the U.S. UDS-3.7 Extensive work was under-
taken to develop the UDS-3 for the cognitive assessment of individ-
uals with MCI, before it was adopted as a standard cognitive assess-
ment in all federally fundedU.S. AD research centers. Althoughdefined
to improve CERAD-NAB performance,31 to date there is no system-
atic evidence on the ability of UDS-3 in detecting MCI. The cUDS
is expected to outperform the CERAD-NAB in the detection of MCI.
Although overlapping with CERAD-NAB and its “-plus” version (Trail
Making, Figures copy/recall; Boston Naming Test and Verbal Fluency
tasks), the Montreal Cognitive Assessment (MoCA) , included in the
cUDS, was shown to clearly outperform the CERAD’s Mini-Mental
State Examination.32 The CERAD word list was demonstrated to be
less sensitive than the California Verbal Learning test,33 and its diag-
nostic and prognostic performance for AD-MCI was demonstrated to
increase by adding the FCSRT34 (32). In addition, the SET allows early
detection of impairment also in patients affected by frontotemporal
lobar degeneration, who may perform well on typical cognitive tests.
Overall, cUDS overlaps with CERAD to a considerable extent but is
devised to be more sensitive to mild, atypical, and non-AD conditions.
AlthoughCERAD-plushas specific normativevalues forUS-English and
German populations (Supplemental Table S2), UDS-3 local analogues
are frequently used in European memory clinics with local norms for
most countries. Alignment with the NACC UDS-3 sets this European
proposal up for improved sensitivity to MCI due to different neurode-
generative causes and for a possibly wider international consensus.
In addition to CERAD and UDS-3, the Neuropsychological Norma-
tive Project (CN-NORM)8 (Supplemental Table S2) has selected and
recommended tests for harmonized assessment of MCI for Chinese
memory clinics. Besides some overlap with the cUDS (eg, trail mak-
ing, digit span and fluency tests, and the memory binding test35 that,
like the FCSRT, uses a controlled learning paradigm minimizing the
use of individual strategies), the CN-NORM battery covers cognitive
domainsmore extensively than the cUDS. In particular, it allows amore
thorough assessment of attentional, perceptual-motor, and social func-
tions. This main difference between the cUDS and the CN-NORM con-
sists of the fact that the cUDS aims to provide objective evidence of
impairment without the aim to identify pathophysiology, because it is
devised for a biomarker-based diagnostic procedure. This differs from
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the CN-NORM initiative, that is not expressly restricted to biomarker-
based procedures and consistently provides more thorough cognitive
assessment requiring additional measures. A short battery, however,
has greater potential to be adopted in EU countries. Nevertheless,
futuredevelopments aimed to improve theassessmentof cognitive and
social functions not assessed by the current cUDS may consider the
Chinese standard and seek further consistency across Western and
Eastern countries.
Previous initiatives selecting and recommending tests for standard
assessment relate to research on preclinical AD (European Preven-
tion of Alzheimer’s Disease [EPAD] and Alzheimer’s disease cognitive
composite [PACC], Supplemental Table S2),36,37 a different context of
use relative to the cUDS. The brevity of PACC makes it an interesting
option for detecting MCI, and decreased scores were associated with
MCI in research cohorts.37,38 Its potential in detectingMCI patients in
memory clinics, not yet explored, is expected to be lower than cUDS.
First, cUDS also includes a test for MCI due to non- or atypical AD.
Moreover, the mentioned limitations of logical memory test16,17,19–22
and of the Mini-Mental State Examination (MMSE)32 are consistent
with the demonstrated improved performance of PACCafter removing
MMSE and including semantic and executive assessment.39,40 APACC-
like composite can be derived from the cUDS; however, future develop-
ments of initiatives aimed at assessing individuals at preclinical (PACC,
EPAD) and clinical (cUDS, UDS-3, CN-NORM) disease stage may try to
seek consistency across each other (eg, FCSRT is already included both
in PACC and cUDS). Bridging these different contexts of use may pro-
vide continuity of assessment, thereby sparingmoney andeffort, if pre-
clinical assessment should be adopted for future population screening
in the future.
The methodology we propose to produce normative data and cut-
off values for impairment is not new in terms of the need for cor-
rection itself but is new as it tries to align the validation of different
tests and of tests in different languages to a common methodological
standard. The age range of controls providing normative values (40+)
allows the detection of early onset cases; the standard classification
of education, although based on only three levels, guarantees a reli-
able comparison across countries characterized by very different edu-
cational systems, which can hardly be captured in a harmonized frame-
work. Although such compromises are required to achieve a minimum
and feasible harmonization, neuropsychological research groups are
encouraged to provide additional, finer normative values for research
aims, for other contexts of use, or to better account for less repre-
sented groups (eg, elderly with very low educational attainments). Fur-
ther stratification for variables like residence in urban versus rural
areasmay also be included if possible.Other possibly confounding vari-
ables, like ethnicity, may have a less consistent effect in Europe than
in the United States, as migration waves are currently variable and
variably handled. On the other hand, norms based on “robust” control
samples (ie, subjects whose normal cognition is documented over lon-
gitudinal evaluations), or on individuals free from pathology or risk fac-
tors for neurocognitive disorders, may also be of interest for research
aims, and may be required in future clinical applications, but are not
pertinent to the proposed standard assessment aimed at detecting
mild impairment from a clinical rather than pathophysiological point
of view.
Further fine-tuning of the cUDS is warranted to meet practical con-
straints to implementation, to assess other dimensions (eg, motiva-
tional level, malingering), or to provide more balanced testing of the
different cognitive domains, similar to the CN-NORM battery. Newly
developed hypothesis-driven tests may increase sensitivity (Supple-
mental Section 2).Moreover, consistency of administration should also
be achieved across centers, raters, and time through specific method-
ological procedures defining standard administration, data entry, score
computation, and ascertaining compliance and reliability over time,
similar to other diagnostic procedures. Score conversion tools and
demonstration of backward compatibility with local batteries are
also required, to shift to the new standard, as is the development
of copyright-free tests analogous to UDS-3, of local normative data
(Box 2), and of digital infrastructure to assist the harmonized assess-
ment (Supplemental Section 3).
Within this initiative, we have tried to take advantage of the knowl-
edge and experience gained in different research and clinical contexts.
Although not entirely new in nature, this is among the first efforts
trying to converge such knowledge into a comprehensive harmonized
procedure for the reliable assessment of patients with MCI possibly
serving both clinical and research aims. This approach was maximized
by the support and participation of several relevant consortia (Sup-
plemental Box S1), most importantly the European Alzheimer’s Dis-
ease Consortium. The Alzheimer’s Association International Society
to Advance Alzheimer’s Research and Treatment (ISTAART) Profes-
sional Interest Area on Cognition has initiated a Workgroup on Har-
monization of Assessment that will also help bring the relevant groups
together to review, evaluate, and make recommendations on conver-
gence. It should be noted, however, that representation in this pro-
cess was limited by logistics and feasibility, penalizing clinicians not
engaged in research at this step. Another major limitation that we did
not address consists of the heterogeneous definition of MCI. Differ-
ent definitions have been applied, but ideally a consensus should be
achieved upstream of a test battery selection. Nevertheless, a stan-
dard selection of tests is a valuable starting point for subsequent more
thorough harmonization. The opportunity to benefit from digital tech-
nology (Supplemental Section 3) to assist the standardized assess-
ment exists but requires additional consensual development and imple-
mentation while respecting clinical and scientific principles underly-
ing standard assessment for neurocognitive disorders. Future devel-
opments may allow for more accurate and reliable assessment, espe-
cially relative to confounders that cannot be stratified and corrected
for in a satisfactory way based on pen-and-pencil tests and tradition-
ally collected normative values. Finally, the number and complexity of
the variables processed in this consensus was so high that formal tra-
ditional consensus procedures (eg, Delphi panel) could not be applied
from the beginning to each of them for reasons of feasibility. Future
developments should try to use formal methods. Despite these limita-
tions, this first step toward harmonization in memory clinics can help
developmoremodern and efficient clinical procedures for neurocogni-
tive disorders through the consistent definition of normal controls and
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methodological procedures for the production of norms, the harmo-
nization across tests and languages, and the attempt to seek for extra-
European convergence. It will optimize costs and reliability, aligning
diagnostic procedures across centers, with the demonstrated informa-
tive value of diagnostic tools, and with the therapeutic value of avail-
able treatment expected to slow down progression and improve the
quality of life of patients and caregivers41 (34).
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